Cover Image
市場調查報告書

全球癌症治療藥藥物遞輸市場分析

Analysis of the Global Oncology Drug Delivery Market

出版商 Frost & Sullivan 商品編碼 325329
出版日期 內容資訊 英文 85 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球癌症治療藥藥物遞輸市場分析 Analysis of the Global Oncology Drug Delivery Market
出版日期: 2015年02月24日 內容資訊: 英文 85 Pages
簡介

本報告提供全球癌症治療藥藥物遞輸市場相關調查分析,市場概要,競爭策略,關於推動因素與阻礙因素驗證,預測與趨勢,市場區隔分析,各地區分析等也包含,提供著有系統的資訊。

第1章 摘要整理

第2章 市場概要

  • 市場背景
  • 市場區隔
  • 癌症治療藥藥物遞輸的整體市場:各給藥類型的區分
  • 癌症治療藥藥物遞輸的整體市場:各地區的區分
  • 癌症治療藥藥物遞輸的整體市場:各前五名公司的區分
  • 癌症的疼痛管理市場

第3章 競爭策略

  • 新的市場機會
  • 癌症治療藥藥物遞輸市場上產品的開發平台
  • 癌症治療藥藥物遞輸市場上魅力

第4章 推動因素與阻礙因素:癌症治療藥藥物遞輸的整體市場

  • 推動市場要素
  • 推動市場要素的說明
  • 阻礙市場要素
  • 阻礙市場要素的說明

第5章 預測與趨勢:癌症治療藥藥物遞輸的整體市場

  • 評估
  • 預測的前提條件
  • 收益預測
  • 各市場區隔的收益預測
  • 收益預測相關考察
  • 口服/注射用藥物遞輸系統
  • 波特的五力分析

第6章 注射用藥物遞輸系統市場區隔分析

  • 評估
  • 注射用藥物遞輸系統市場區隔:收益預測
  • 收益預測相關考察
  • 注射用藥物遞輸系統市場區隔:競爭評估

第7章 口服用藥物遞輸系統市場區隔分析

  • 評估
  • 口服用藥物遞輸系統市場區隔
  • 收益預測相關考察
  • 口服腫瘤溶解劑:過去、現在、未來的選項
  • 口服用藥物遞輸系統市場區隔:競爭評估

第8章 各地區的機會

  • 美國市場:癌症治療藥藥物遞輸市場概要
  • 美國的癌症治療藥藥物遞輸市場:收益預測
  • 歐洲市場:癌症治療藥藥物遞輸系統概要
  • 歐洲的癌症治療藥藥物遞輸市場:收益預測
  • 其他地區的癌症治療藥藥物遞輸市場:抗癌劑給藥系統概要
  • 其他地區的癌症治療藥藥物遞輸市場:收益預測

第9章 各技術的機會

  • 奈米藥物遞輸
  • 現在已上市的奈米藥物遞輸系統
  • 奈米藥物遞輸系統:區分
  • 富有魅力的奈米藥物遞輸系統
  • 主要的奈米藥物遞輸系統
  • 鼻腔內藥物遞輸

第10章 值得注意的主要企業

  • Becton, Dickinson and Company (BD)
  • Evotec AG
  • Juno Therapeutics, Inc.
  • West Pharmaceuticals
  • NEONC Technologies Inc. (NTI)

第11章 總論

第12章 附錄

目錄
Product Code: P874-01-00-00-00

Future Impact of Emerging Technologies

The global oncology drug delivery market (or oncolytics market) was worth $91.00 billion in 2013 and has been growing at an annual rate of 5.0%. The market, which includes drug delivery systems for cancer therapy and cancer pain, is expected to generate $100.96 billion in 2015. The oral drug delivery systems segment accounted for an estimated 25.0% of the total global market in 2013 and will continue to grow stronger in 2015. Currently, the injectable drug delivery system segment leads the cancer drug delivery market; however, nanoparticles (including micro-needles, patches, and orals) are expected to lead the market in the future.

Key Questions This Study Will Answer

  • Is the market growing? How long will it continue to grow, and at what rate?
  • Who are the key competitors in this market?
  • What are the major drivers and restraints in this market?
  • Which is the most attractive segment in the total oncology drug delivery market?
  • What are the upcoming technologies in the oncology drug delivery market?

Table of Contents

1. EXECUTIVE SUMMARY

Executive Summary

  • 1. Key Findings
  • 2. Key Findings (continued)
  • 3. Key Findings-Options in the Oncology Drug Delivery Market
  • 4. Scope and Segmentation
  • 5. Key Questions This Study Will Answer
  • 6. Measurements
  • 7. CEO's Perspective
  • 8. Key Technologies to Watch
  • 9. 3 Key Predictions

2. MARKET OVERVIEW

Market Overview

  • 1. Market Background
  • 2. Market Segmentation
  • 3. Total Oncology Drug Delivery Market-Segmentation by Type of Delivery
  • 4. Total Oncology Drug Delivery Market-Segmentation by Type of Delivery (continued)
  • 5. Total Oncology Drug Delivery Market-Segmentation by Region
  • 6. Total Oncology Drug Delivery Market-Segmentation by Top 5 Competitors
  • 7. Cancer Pain Management Market

3. COMPETITIVE PLAYBOOK

Competitive Playbook

  • 1. New Market Opportunities
  • 2. Pipeline of Products in Oncology Drug Delivery Market
  • 3. Attractiveness in Oncology Drug Delivery Market

4. DRIVERS AND RESTRAINTS-TOTAL CANCER DRUG DELIVERY MARKET

Drivers and Restraints-Total Cancer Drug Delivery Market

  • 1. Market Drivers
  • 2. Drivers Explained
  • 3. Drivers Explained (continued)
  • 4. Market Restraints
  • 5. Restraints Explained

5. FORECAST AND TRENDS-TOTAL CANCER DRUG DELIVERY MARKET

Forecast and Trends-Total Cancer Drug Delivery Market

  • 1. Measurements
  • 2. Forecast Assumptions
  • 3. Revenue Forecast
  • 4. Revenue Forecast by Segment
  • 5. Revenue Forecast Discussion
  • 6. Oral or Injectable Drug Delivery Systems-New Options for Payors
  • 7. Oral or Injectable Drug Delivery Systems-New Options for Payors (continued)
  • 8. Oral or Injectable Drug Delivery Systems-New Options for Payors (continued)
  • 9. Oral or Injectable Drug Delivery Systems-New Options for Payors (continued)
  • 10. Porter's 5 Force Analysis

6. INJECTABLE DRUG DELIVERY SYSTEM SEGMENT ANALYSIS

Injectable Drug Delivery System Segment Analysis

  • 1. Measurements
  • 2. Injectable Drug Delivery System Segment-Revenue Forecast
  • 3. Revenue Forecast Discussion
  • 4. Injectable Drug Delivery System Segment-Competitive Assessment

7. ORAL DRUG DELIVERY SYSTEM SEGMENT ANALYSIS

Oral Drug Delivery System Segment Analysis

  • 1. Measurements
  • 2. Oral Drug Delivery System Segment
  • 3. Revenue Forecast Discussion
  • 4. Oral Oncolytic-Past, Present, and Future Options
  • 5. Oral Drug Delivery System Segment-Competitive Assessment

8. OPPORTUNITIES BY REGION

Opportunities by Region

  • 1. US Market-Overview of Oncology Drug Delivery Market
  • 2. US Oncology Drug Delivery Market-Revenue Forecast
  • 3. Europe Market-Overview of Cancer Drug Delivery System
  • 4. Europe Oncology Drug Delivery Market-Revenue Forecast
  • 5. RoW Oncology Drug Delivery Market-Overview of Cancer Drug Delivery System
  • 6. RoW Oncology Drug Delivery Market-Revenue Forecast

9. OPPORTUNITY BY TECHNOLOGY

Opportunity by Technology

  • 1. Nano Drug Delivery-Future of Cancer Drug Delivery Systems
  • 2. Currently Marketed Nano Drug Delivery Systems-All Injectable Drug Delivery Systems
  • 3. Nano Drug Delivery System-Segmentation
  • 4. Attractive Nano Drug Delivery Systems
  • 5. Key Nano Drug Delivery Systems-High Potential and Equally Attractive Technology for Future
  • 6. Intra-nasal Drug Delivery-Next Option in Cancer Pain

10. KEY COMPANIES TO WATCH

Key Companies to Watch

  • 1. Becton, Dickinson and Company (BD)
  • 2. Evotec AG
  • 3. Juno Therapeutics, Inc.
  • 4. West Pharmaceuticals
  • 5. NEONC Technologies Inc. (NTI)

11. CONCLUSION

Conclusion

  • 1. Future of Cancer Drugs-Drugs in Cases where Tumour will no Longer Respond to Standard Therapy
  • 2. Conclusions
  • 3. Frost & Sullivan Awards
  • 4. Legal Disclaimer

12. APPENDIX

Appendix

  • 1. Methodology
  • 2. Learn More-Next Steps
Back to Top